Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
68462-0897-10 68462-0897 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug. 9, 2023 In Use
55150-0450-01 55150-0450 MITOMYCIN MITOMYCIN 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 30, 2023 In Use
55150-0451-01 55150-0451 MITOMYCIN MITOMYCIN 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 30, 2023 In Use
55150-0452-01 55150-0452 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Oct. 30, 2023 In Use
43598-0308-23 43598-0308 Plerixafor Plerixafor 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous Nov. 6, 2023 In Use
00781-3532-12 00781-3532 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Nov. 1, 2023 In Use
00093-7769-24 00093-7769 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 23, 2023 In Use
42043-0390-00 42043-0390 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2016 In Use
42043-0390-02 42043-0390 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2016 In Use
42043-0390-20 42043-0390 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2016 In Use
42043-0390-21 42043-0390 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2016 In Use
42043-0390-40 42043-0390 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2016 In Use
42747-0726-01 42747-0726 Granisetron Sancuso 3.1 mg/24h Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Transdermal Sept. 12, 2008 In Use
42747-0726-72 42747-0726 Granisetron Sancuso 3.1 mg/24h Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Transdermal Sept. 12, 2008 In Use
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
70518-2023-00 70518-2023 Methylprednisolone sodium succinate SOLU-MEDROL 125.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous April 15, 2019 July 10, 2020 In Use
70518-2023-01 70518-2023 Methylprednisolone sodium succinate SOLU-MEDROL 125.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous April 15, 2019 July 10, 2020 In Use
70518-2023-02 70518-2023 Methylprednisolone sodium succinate SOLU-MEDROL 125.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Aug. 27, 2021 Aug. 30, 2021 In Use
70529-0045-01 70529-0045 Dexamethasone Sodium Phosphate Viadox 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Aug. 1, 2018 In Use
70529-0045-02 70529-0045 Dexamethasone Sodium Phosphate Viadox 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Aug. 1, 2018 In Use
70529-0045-05 70529-0045 Dexamethasone Sodium Phosphate Viadox 10.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Aug. 1, 2018 In Use
70529-0048-01 70529-0048 Triamcinolone Acetonide Protherix 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Sept. 1, 2018 In Use
70529-0048-02 70529-0048 Triamcinolone Acetonide Protherix 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Sept. 1, 2018 In Use
70529-0048-03 70529-0048 Triamcinolone Acetonide Protherix 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intramuscular Sept. 1, 2018 In Use
73358-0210-08 73358-0210 Docetaxel Anhydrous Docetaxel Anhydrous 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 17, 2022 In Use
73358-0210-16 73358-0210 Docetaxel Anhydrous Docetaxel Anhydrous 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 17, 2022 In Use
70518-2676-00 70518-2676 Prednisone PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 7, 2020 In Use
70518-2676-01 70518-2676 Prednisone PREDNISONE 5.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 22, 2020 In Use
00378-7732-05 00378-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Oct. 9, 2014 In Use
00378-7732-93 00378-7732 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-05 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 Oct. 9, 2014 In Use
00378-7734-93 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00378-7734-97 00378-7734 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral June 25, 2007 May 31, 2024 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec. 8, 2017 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0193-01 00069-0193 Bosutinib monohydrate, Bosutinib BOSULIF 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Dec. 18, 2017 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 Dec. 31, 2028 In Use
60687-0455-21 60687-0455 Abiraterone Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Nov. 1, 2019 In Use
00480-4184-89 00480-4184 Pazopanib Pazopanib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms Oral Oct. 20, 2023 In Use
00310-4505-25 00310-4505 Tremelimumab IMJUDO 25.0 mg/1.25mL Immunotherapy Checkpoint Inhibitor CTLA-4 Intravenous Oct. 21, 2022 In Use
60687-0729-01 60687-0729 Dexamethasone Dexamethasone 6.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral April 27, 2023 In Use
63459-0177-14 63459-0177 Omacetaxine Mepesuccinate Synribo 3.5 mg/mL Chemotherapy Plant Alkaloid BCR-ABL Subcutaneous Nov. 19, 2012 April 30, 2024 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 July 31, 2024 In Use
68001-0534-36 68001-0534 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 31, 2022 April 29, 2025 In Use
68001-0564-22 68001-0564 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 10, 2023 In Use
68001-0565-28 68001-0565 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 10, 2023 In Use
69543-0371-10 69543-0371 Palonosetron hydrochloride Palonosetron hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 Jan. 31, 2026 In Use

Found 10,000 results in 7 millisecondsExport these results